Basic information
- CAS
181785-84-2- Standard SMILES
Nc1nc(=O)n([C@@H]2C=C[C@H](CO)O2)cc1F- InChIKey
HSBKFSPNDWWPSL-VDTYLAMSSA-N- Molecular formula
- C9H10FN3O3
- Average molar mass
- 227.19 g/mol
- Monoisotopic mass
- 227.07061935
Overview
Elvucitabine is a nucleoside reverse transcriptase inhibitor analog of cytosine. Elvucitabine has activity against HIV and chronic hepatitis B.
Names & identifiers
- Preferred name
- Elvucitabine
- IUPAC
- 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
- English name
- 4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
- Molecular formula
- C9H10FN3O3
- Molecular weight
- 227.19
Names & synonyms
Elvucitabine181785-84-2beta-L-Fd4CL-Fd4CACH-126443ACH-126,443ElvucitabinaM09BUF90C0ACH 126443ACH 126,4434-amino-5-fluoro-1-((2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidin-2(1H)-oneDTXSID20171185
Show more names
L-D4FcTY-202L-Fd 4CAids060327Aids-060327.beta.-L-Fd4c.beta.-L-2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
4-amino-5-fluoro-1-[(2s,5r)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1h)-onebeta-L-2',3'-Dideoxy-2',3'-didehydro-5-fluorocytidine2(1H)-Pyrimidinone, 4-amino-1-((2S,5R)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-5-fluoro-2(1H)-Pyrimidinone, 4-amino-1-[(2S,5R)-2,5-dihydro-5-(hydroxymethyl)-2-furanyl]-5-fluoro-elvucitabinumRefChem:590730DTXCID10936764-amino-5-fluoro-1-((2S,5R)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-1,2-dihydropyrimidin-2-one
Database identifiers
- CAS
Properties
Computed structural properties
- XLogP
- -1.3
- Topological polar surface area
- 88.2 Ų
- Hydrogen bond donors
- 2
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 2
- Heavy atoms
- 16
- Formal charge
- 0
- Complexity
- 405
Experimental & physicochemical properties
DrugsPharmaceuticals -> Listed in ZINC15
Physicochemical properties
- Boiling point
- 394.9 · 394.9±52.0 °C(Predicted)
- Density
- 1.66 · 1.66±0.1 g/cm3(Predicted)
- pka
- 14.28 · 14.28±0.10(Predicted)
- FDA UNII
- 9 BUF90C0 · M09BUF90C0
Chemistry & industry
Pharmacology
Mechanism of Action
Elvucitabine is a L-cytosine Nucleoside analog Reverse Transcriptase Inhibitor (NRTIs) anti-HIV drug. NRTI's inhibit the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body.
MeSH Pharmacological Classification
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
Applications
UsesA novel antiviral agent.
Suppliers14 total
LGM Pharma1-(800)-881-8210 · [email protected]
上海波以尔化工有限公司[email protected]
安耐吉化学&3A（安徽泽升科技有限公司）021-58432009 400-005-6266 · [email protected]
上海梅凯科技有限公司021-68689288 15300790979 · [email protected]
凯试(上海)科技有限公司021-50135380 · [email protected]
AdooQ BioScience, LLC
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…